[Federal Register Volume 84, Number 185 (Tuesday, September 24, 2019)]
[Notices]
[Page 50094]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-20575]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF STATE

[Public Notice 10897]


Notice of Public Meeting of the U.S. President's Emergency Plan 
for AIDS Relief (PEPFAR) Scientific Advisory Board

    In accordance with the Federal Advisory Committee Act (FACA), the 
PEPFAR Scientific Advisory Board (hereinafter referred to as ``the 
Board'') will meet on Wednesday, October 16, 2019 at the offices of the 
U.S. Global AIDS Coordinator and Health Diplomacy located at 1800 G St. 
NW, Suite 10-300, Washington, DC 20006. The meeting is expected to run 
from 8:30 a.m. until 5:30 p.m. and is open to the public.
    The Board is established under the general authority of the 
Secretary of State and the Department of State (``the Department'') as 
set forth in Title 22 of the United States Code, in particular Section 
2656 of that Title, and consistent with the Federal Advisory Committee 
Act, as amended (5 U.S.C. Appendix).
    The meeting will be hosted by U.S. Global AIDS Coordinator, 
Ambassador-at-Large Deborah Birx, M.D., who leads the coordination and 
implementation of PEPFAR, and the Board Chair, Dr. Carlos del Rio. The 
Board serves the U.S. Global AIDS Coordinator in a solely advisory 
capacity concerning scientific, implementation, and policy issues 
related to the U.S. response to HIV/AIDS globally. These issues evolve 
and are of concern as they influence the priorities and direction of 
PEPFAR, the content of national and international strategies for 
program implementation, and the role of PEPFAR in international 
discourse regarding an appropriate and resourced response and we 
advance towards epidemic control of HIV/AIDS. Topics for the October 16 
meeting will include a report out from an expert working group on the 
use of HIV recency testing; updates on PEPFAR 2019 programmatic 
activities; updates on next-generation HIV biomedical prevention; 
updates on universal test and treat; and a risk/benefit discussion of 
the transition to dolutegravir based ART regimens.
    The public may attend this meeting as capacity allows. Admittance 
to the meeting will be by means of a pre-arranged clearance list. In 
order to be placed on the list and, if applicable, to request 
reasonable accommodation, please register online via the following: 
https://forms.gle/vrD4HgcbLQ7aiq4p6 no later than Monday, September 30. 
While the meeting is open to public attendance, the Board will 
determine procedures for public participation. Requests for reasonable 
accommodation that are made after 12 p.m. on September 30, 2019 may not 
be possible to fulfill.
    For further information about the meeting, please contact Dr. Sara 
Klucking, Designated Federal Officer for the Board, Office of the U.S. 
Global AIDS Coordinator and Health Diplomacy at [email protected].

Sara R. Klucking,
Acting Director for Research and Science.
[FR Doc. 2019-20575 Filed 9-23-19; 8:45 am]
BILLING CODE 4710-10-P